J&J and Takeda open up an Israeli biotech incubator

Johnson & Johnson ($JNJ) has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation. The incubator, dubbed FutuRx, is one of J&J's 5 worldwide Innovation Centers, The Times of Israel reports, and its first two members, Hepy Biosciences and XoNovo, are already getting to work on early-stage drugs. News

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.